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Abstract
The present document is the result of a consensus reached by a panel of experts from European
and non-European countries on Occupational Rhinitis (OR), a disease of emerging relevance which
has received little attention in comparison to occupational asthma. The document covers the main
items of OR including epidemiology, diagnosis, management, socio-economic impact, preventive
strategies and medicolegal issues. An operational definition and classification of OR tailored on that
of occupational asthma, as well as a diagnostic algorithm based on steps allowing for different levels
of diagnostic evidence are proposed. The needs for future research are pointed out. Key messages
are issued for each item.
Key messages
Definition and classification
• Occupational rhinitis is an inflammatory disease of the
nose, which is characterized by intermittent or persistent
symptoms (i.e., nasal congestion, sneezing, rhinorrea,
itching), and/or variable nasal airflow limitation and/or
hypersecretion due to causes and conditions attributable
to a particular work environment and not to stimuli
encountered outside the workplace
• Work-related rhinitis may be distinguished into: (1)
occupational rhinitis that is due to causes and conditions
attributable to a particular work environment (2) work-
exacerbated rhinitis that is pre-existing or concurrent rhin-
itis exacerbated by workplace exposures
Epidemiology
• Surveys of workforces exposed to sensitizing agents indi-
cate that OR is 2 to 4 times more common than OA,
Published: 3 March 2009
Respiratory Research 2009, 10:16 doi:10.1186/1465-9921-10-16
Received: 5 November 2008
Accepted: 3 March 2009
This article is available from: http://respiratory-research.com/content/10/1/16
© 2009 Moscato et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Page 1 of 20
(page number not for citation purposes)
Respiratory Research 2009, 10:16 http://respiratory-research.com/content/10/1/16although the contribution of workplace exposures to the
general burden of rhinitis remains unknown
• The level of exposure is the most important determinant
of IgE-mediated sensitization to occupational agents and
OR
• Atopy is a risk factor for the development of IgE-medi-
ated sensitization to HMW agents, but the association
with clinical OR due to HMW agents is less well substan-
tiated
Relationships with occupational asthma
• The majority of patients diagnosed with OA also suffers
from OR, which most often precedes the development of
OA, especially when HMW agents are involved
• OR is associated with an increased risk of asthma,
although the proportion of subjects with OR who will
develop OA remains uncertain
Investigation and diagnostic approach
• Questionnaires and the clinical history have a low spe-
cificity for diagnosing OR
• Immunological tests (skin prick tests and specific IgE
antibodies) are sensitive but not specific tools for diagnos-
ing OR due to most HMW agents and some LMW agents
(i.e., platinum salts, acid anhydrides, and reactive dyes)
• In the presence of work-related rhinitis symptoms,
objective assessment using nasal provocation challenges
in the laboratory or at the workplace should be strongly
recommended
Management
• Complete avoidance of exposure to the agent causing
allergic OR should still be recommended as the safest and
most effective therapeutic option
• When complete elimination of causal exposure is
expected to induce important adverse socio-economic
consequences, reduction of exposure with relevant phar-
macotherapy may be considered an alternative approach,
especially in workers with a lower risk of developing
asthma (e.g., workers without non-specific bronchial
hyperresponsiveness, with mild/recent disease or with a
short expected duration of exposure); these workers
should however benefit from close medical surveillance
aimed at an early detection of OA
Socio-economic impact
• The socio-economic impact of OR is unknown, but is
likely to be substantial in terms of work productivity as
can be extrapolated from data available for allergic rhinitis
in general
Prevention
• Primary prevention strategies should focus on reducing
exposure to potentially sensitizing agents
• Identification and exclusion of susceptible workers is
not efficient, particularly when the marker of susceptibil-
ity (e.g. atopy) is prevalent in the general population
• Surveillance programmes aimed at an early identifica-
tion of OR should include periodic administration of
questionnaires and immunological tests when available
• Surveillance of workers should focus on the first 2 to 5
years after entering exposure
• The possibility of OA should be carefully evaluated in all
workers with OR
Medico-legal aspects
• Workers with OR should theoretically be considered
impaired on a permanent basis for the job that caused the
condition as well as for jobs with similar exposures
• Compensation of OR should aim at providing incen-
tives to accommodate workers to unexposed jobs and
offering vocational rehabilitation programs in order to
minimize the adverse socio-economic consequences of
the disease
Introduction
The health and socio-economic impact of rhinitis, as well
as the interaction between upper and lower airways have
been emphasized in recent years [1-8]. By contrast, little
attention has been paid to occupational rhinitis (OR),
although it is increasingly acknowledged that the burden
of this condition is largely underestimated in comparison
with occupational asthma (OA) [9-12] [see also Figure 1].
There is currently no consensus on the definition and clas-
sification of OR. In addition, diagnostic procedures and
strategies for the management of subjects with OR remain
poorly standardized. This is a particularly important point
as an accurate and early recognition of OR in surveillance
programs is not only important per se, but is also useful in
the prevention and early diagnosis of OA.
The purpose of this document was to provide a compre-
hensive and critical review of available information on the
different aspects of OR including diagnostic procedures,
management, societal burden, and preventive strategies.
The principal objective was to issue key messages and con-
sensus recommendations based on existing scientific evi-Page 2 of 20
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from different European and non European countries.
Definition and classification
The most widely cited definition of rhinitis has been for-
mulated by the International Consensus Report and states
that 'rhinitis is defined as inflammation of the lining of the
nose, characterized by one or more of the following symptoms:
nasal congestion, rhinorrhea, sneezing, and itching' [1,13].
This International Consensus Report has proposed an
operational definition of rhinitis which was based solely
on symptoms and would require the presence of 'two or
more nasal symptoms for more than one hour on most days',
although these criteria have never been formally validated
[14-16].
Most previously published definitions of OR were based
on the temporal relationship between nasal symptoms
and workplace exposure [13,17-20], while a few others
also refer to the underlying inflammation [12,21]. How-
ever, the major symptoms of OR (i.e., sneezing, rhinor-
rhea, nasal congestion, and itching) are similar to those of
non-occupational rhinitis. Defining OR based only on
work-related symptoms would therefore suffer the limita-
tion of being inaccurate [22], as already outlined for OA
[23].
In addition, the similarities and tight interactions between
rhinitis and asthma [1-8] support the need for homogene-
ous definitions of OR and OA. The most widely accepted
definition of OA refers to the pathophysiological changes
that occur in the lower airways, i.e. 'variable airflow limita-
tion and/or bronchial hyperresponsiveness and/or inflamma-
tion' [24,25]. A similar approach cannot easily be
translated to OR because: (1) nasal airflow limitation is
not always present in OR; and (2) the various methods
Parallel classification of occupational rhinitis and asthmaFigure 1
Parallel classification of occupational rhinitis and asthma. The Table classifies occupational rhinitis according to the 
most recent classification of occupational asthma. RADS, Reactive Airways Dysfunction Syndrome; RUDS, Reactive Upper Air-
ways Dysfunction Syndrome).
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sponsiveness, and inflammation have not been thor-
oughly validated [26,27], and (3) these procedures are
still largely underused in clinical practice. Nevertheless,
considering that inflammatory changes of the mucosa are
the common feature of both rhinitis and asthma [1-8,12],
the following consensus definition of OR is proposed:
'Occupational rhinitis is an inflammatory disease of the
nose, which is characterized by intermittent or persistent
symptoms (i.e., nasal congestion, sneezing, rhinorrea, itch-
ing), and/or variable nasal airflow limitation and/or hyper-
secretion due to causes and conditions attributable to a
particular work environment and not to stimuli encoun-
tered outside the workplace'.
The central concept of this broad definition is the causal
relationship between work exposure and the development
of the disease. In addition, this definition is based on
demonstrable pathophysiological changes, and it does
not place restriction according to the underlying mecha-
nism.
There is accumulating evidence that the workplace envi-
ronment can induce or trigger a wide spectrum of rhinitis
conditions involving immunological and non-immuno-
logical mechanisms [16,20,28,29]. These various condi-
tions should be referred to as 'work-related rhinitis' and
should be further distinguished according to the clinical
features, etiopathogenic mechanisms, and the strength of
the evidence supporting the causal relationship.
According to the revised nomenclature for allergy recently
recommended by the European Academy of Allergy and
Clinical Immunology [30] and the classification of work-
related asthma proposed by panels of experts [24,25,31]
different types of 'work-related rhinitis' may be delineated
as detailed below and summarized in Figure 1. This review
will, however, focus on immunologically-mediated OR,
since there is only scarce data on the other forms of work-
related rhinitis.
Occupational rhinitis
Allergic OR
Work-related rhinitis symptoms are caused by immuno-
logically-mediated hypersensitivity reactions resulting
from antibody- or cell-mediated mechanisms. This entity
is characterized clinically by the development of nasal
hypersensitivity to a specific occupational agent appearing
after a latency period, which is necessary to acquire immu-
nological sensitization to the causal agent. Once initiated,
the symptoms recur on re-exposure to the sensitizing
agent at concentrations not affecting other similarly
exposed workers. The symptoms can be intermittent or
persistent according to the frequency and intensity of
exposure to the causal agent. In allergic OR, the causal role
of occupational agents can be documented on an individ-
ual basis through nasal provocation test (NPT), showing
reduction of nasal patency, increased volume of nasal
secretions, and/or nasal inflammation. Allergic OR
encompasses both IgE-mediated OR and non-IgE-medi-
ated OR.
1. IgE-mediated OR: Can be caused by a wide variety of
high-molecular weight (HMW) agents (i.e. glycoproteins
from vegetal and animal origin) and some low-molecular-
weight-agents (LMW) for which an IgE-mediated mecha-
nism has been proven, such as platinum salts, reactive
dyes, and acid anhydrides.
2. Non-IgE-mediated OR: Can be induced by LMW agents
(e.g. isocyanates, persulphate salts, woods) acting as hap-
tens for which the allergic mechanism has not yet been
fully characterized.
Non-allergic OR
This category encompasses different types of rhinitis
caused by the work environment through irritant, non-
immunological mechanisms. It has been documented
that single or multiple exposures to very high concentra-
tions of irritant compounds can lead to transient or per-
sistent symptoms of rhinitis [32-34]. Such cases of acute-
onset 'irritant-induced OR' usually occur without a latency
period, although the absence of latency may be obscured
when workers are repeatedly exposed to high levels of irri-
tants at work. This entity is quite similar to the situation
of 'reactive airways dysfunction syndrome' (RADS)
[25,31,35], so that the term 'reactive upper airways dysfunc-
tion syndrome' (RUDS) has been proposed [36]. Biopsies of
the nasal mucosa among individuals with RUDS induced
by chlorine have shown non specific pathologic changes
(i.e., lymphocytic inflammation of the lamina propria,
epithelial desquamation, defective epithelial cell junc-
tions, and increased numbers of nerve fibres) [32]. In
these cases of irritant-induced OR, evidence supporting a
causal relationship with the workplace can be drawn only
from the temporal association between exposure to unu-
sually high levels of irritants and the development of rhin-
itis symptoms (or other objective indices of the disease).
The term 'irritant-induced OR' may also refer to symptoms
of rhinitis reported by subjects repeatedly exposed at work
to irritants (vapours, fumes, smokes, dusts) without iden-
tifiable exposure to high concentration of irritants. A vari-
ety of occupational exposures have been associated with
rhinitis symptoms, nasal airflow obstruction, and/or
nasal inflammation, usually with a predominant neu-
trophilic component, including ozone, volatile organic
compounds, fuel oil ash, grain and cotton dust, formalde-
hyde, chlorine, wood dust, thermal degradation productsPage 4 of 20
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toms may be experienced only during exposure to irritants
at work or may be persistent, presenting both at work and
off work.
The term 'corrosive rhinitis' has been used to describe the
most severe form of 'irritant-induced OR', which is char-
acterized by permanent inflammation of the nasal
mucosa (sometimes associated with ulcerations and per-
foration of the nasal septum) that may develops after
exposure to high concentrations of irritating and soluble
chemicals [20,29,37].
Work-exacerbated rhinitis
Work-exacerbated rhinitis (WER) should be defined as
pre-existing or concurrent (allergic or non-allergic) rhini-
tis that is worsened by workplace exposures [22,29], while
the disease has not been caused by the work environment.
It is indeed highly likely that rhinitis symptoms can be
triggered by a wide variety of conditions at work, includ-
ing irritant agents (e.g., chemicals, dusts, fumes), physical
factors (e.g., temperature changes), emotions, second-
hand smoke, and strong smells (e.g., perfumes). Epidemi-
ological surveys have usually found high prevalence rates
of work-related nasal symptoms in a variety of workforces,
although IgE-mediated sensitization to occupational
agents was not detected [22,38-42]) or nasal inflamma-
tion was not documented [43-47].
The clinical features of a WER are similar to those of occu-
pational rhinitis, so that the possibility of a WER should
be considered only after careful exclusion of a specific sen-
sitization to a workplace agent through appropriate diag-
nostic procedures. The mechanisms involved in the
development of WER have been scarcely explored. The
nasal response to irritant stimuli show wide inter-individ-
ual variability, and exaggerated reactivity to common
chemical and physical stimuli, and is affected by age, gen-
der, and the presence of allergic rhinitis [48-50].
Epidemiology
Prevalence and incidence
Although rhinitis is a common condition, the prevalence
and incidence of OR in the general population have
almost never been specifically investigated. Analysis of
incident cases of OR reported to the Finnish Register of
Occupational Diseases during the period 1986–1991
showed that occupations at increased risk include furriers,
bakers, livestock breeders, food-processing workers, veter-
inarians, farmers, electronic/electrical products assem-
blers, and boat builders [51].
Cross-sectional studies have been conducted in various
working populations exposed to a wide range of HMW
and LMW agents, as recently reviewed [9]. Prevalence rates
of OR varied from 2% to 87% in workforces exposed to
HMW agents and from 3% to 48% in those exposed to
LMW agents (Table 1). Available data indicate that OR is
usually 2–4 times more prevalent than OA [9,52]. Preva-
lence estimates of rhinitis and OR are largely affected by
the criteria used for identifying the condition [52]. The
incidence of work-related nose symptoms (WRNS) has
been investigated in a few prospective cohort studies that
are summarized in Table 2[38-41,53,54].
Risk factors
Exposure, atopy, and smoking have consistently emerged
as the main potential determinants for the development
of OR.
Level of exposure
A dose-response gradient between the level of exposure
and IgE-mediated sensitization has been substantiated for
various HMW agents, such as laboratory animals [55,56],
flour [57,58], insects [59], alpha-amylase [60], and deter-
gent enzymes [61]. However, much of the evidence relates
more strongly to immunological sensitization (i.e., the
development of specific IgE antibodies) than to clinical
OR [9]. Although the relationships between these two
outcomes are poorly understood, the development of IgE
sensitization to some agents seems to be a strong predic-
tor of rhinitis/asthma symptoms [41,62-64].
Atopy
Atopy has been associated with an increased risk of spe-
cific sensitization to a variety of HMW agents [9,52].
Atopy is associated with OR due to these agents (Table 1)
[41,65,66]. Available studies have provided inconsistent
results regarding the relationships between atopy and OR
or specific sensitization in workers exposed to LMW
agents [9,63] but atopy is unlikely to play a role.
Unlike occupational asthma, the role of genetic factors in
the development of OR has never been specifically
assessed. [67].
Smoking
The relationships between smoking and occupational sen-
sitization, OR, and OA remain controversial [68-70].
Non-specific bronchial hyperresponsiveness
There is some evidence from cohort studies [63,71] that
non-specific bronchial hyperresponsiveness may be asso-
ciated with an increased risk for the subsequent develop-
ment of work-related nasal symptoms.
Relationships with occupational asthma
Increasing scientific evidence shows that among the gen-
eral population asthma and rhinitis might be a unique
disease with manifestations in different sites of the respi-Page 5 of 20
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Table 1: Prevalence and aetiological agents in occupational rhinitis (adapted from reference [9]).
Agents Occupation Prevalence (%)
High molecular weight agents
Laboratory animals Laboratory workers 6–33
Other animal-derived allergens Swine confinement workers 8–23
Insects & mites Laboratory workers, farm workers 2–60
Grain dust Grain elevators 28–64
Flour Bakers 18–29
Latex Hospital workers, textile factory 9–20
Other plant allergens Tobacco, carpet, hot pepper, tea, coffee, cocoa, dried fruit and saffron workers 5–36
Biological enzymes Pharmaceutical & detergent industries 3–87
Fish and seafood protein Trout, prawn, shrimp, crab & clam workers; aquarists & fish-food factory workers 5–24
Low molecular weight agents
Diisocyanates Painters, urethane mould workers 36–42
Anhydrides Epoxy resin production, chemical workers, electric condenser workers 10–48
Wood dust Carpentry & furniture making 10–36
Metals (platinum) Platinum refinery 43
Drugs (psyllium, spiramycin, piperacillin) Health care & pharmaceutical workers 9–41
Chemicals Reactive dye, synthetic fibre, cotton, persulphate, hairdressing, pulp & paper, shoe 
manufacturing
3–30
Table 2: Incidence of occupational asthma and rhinitis
Reference/agent Subjects
N
Years/duration
(yrs) of follow-up
Incidence of OA*
(× 100 person years)
Incidence of OR**
(× 100 person years)
Cullinan el al., 1999/laboratory animals [38] 342 1990–1993/2.7 3.5 7.3
Rodier et al., 2003/laboratory animals [39] 387 1993–1995/3.7 2.7 12.1
Draper et al., 2003/laboratory animals [54] 17300 1999–2000/1.0 0.2 0.3
Cullinan et al., 2001/flour [40] 1990–1993/3.3 4.1 11.8
Gautrin et al., 2002/flour [41] 1993–1997/1.4 NA*** 13.1
Archambault et al., 2001/latex [53] 1993–1995/2.7 1.8 0.7
*OA: occupational asthma; **OR, occupational rhinitis ; ***NA, not available.
Respiratory Research 2009, 10:16 http://respiratory-research.com/content/10/1/16ratory system [2,5,7]. The 'united airway disease' model
describes such a relationship as two clinical manifesta-
tions of a single disorder. The evidence of this relationship
comes from the observation of common epidemiologic
[72], physiopathologic, [73], clinical and therapeutic fea-
tures in both conditions [2,3]. These links have been more
frequently observed when considering allergic mecha-
nisms, but the concept of a unique disease has evolved
and non-allergic mechanisms may be considered as well.
With regard to the association between rhinitis and
asthma of occupational origin, Malo and coworkers have
documented that rhinitis symptoms are common among
subjects with OA, 92% patients with OA reporting symp-
toms of OR [74]. The prevalence of rhinitis symptoms was
not different for HMW and LMW agents, although the
intensity of symptoms was more pronounced for HMW
agents. A recent prospective study carried out in patients
referred to four tertiary care clinics for possible OA,
showed that nasal itching and secretions as well as ocular
itching were satisfactory predictors of the presence of OA
as confirmed by specific inhalation challenges [75]. How-
ever, this likely prediction obtained from questionnaire
items applied for HMW but not for LMW agents.
Symptoms of OR have been reported to develop before
those of OA in 20 to 78% of affected subjects
[22,64,74,76-80]. There is some suggestion that symp-
toms of OR were more often reported to precede OA in
the case of HMW compared to LMW agents [74,77]. A lon-
gitudinal study of patients seeking compensation for OR
from the Finnish Register of Occupational Diseases, fol-
lowed via register linkage showed an increased risk of
asthma (RR 4.8, 95%CI 4.3 to 5.4) among those with OR
compared to subjects with other occupational diseases
[81]. The incidence rate ratio for asthma in workers with
occupational rhinitis varied across occupations, being
highest for farmers and woodworkers [81].
The time-course pertaining to the development of immu-
nological sensitization and nasal or respiratory symptoms
related to the onset of exposure has seldom been exam-
ined. As for environmental allergens, it can be hypothe-
sized that workers first develop immunological reactivity
and subsequent to this, symptoms related to a specific
organ (skin, nasoconjunctival, respiratory), this sequence
being referred to as the 'allergic march'. Among appren-
tices in animal health technology [62], development of
skin reactivity and nasoconjunctival symptoms mainly
occurred in the first two years after starting exposure, con-
firming the findings of a longitudinal study of animal
workers [38], whereas onset of respiratory symptoms was
more common in the second and third year of the appren-
ticeship program. In this study, the predictive value of the
development of work-related nasal symptoms on the sub-
sequent development of probable OA was only 11.4%
over a 44-months period [62]. An annual surveillance
program of workers exposed to laboratory animals (582
workers contributing 2414 person-years) found that the
probability of experiencing asthma symptoms by the 11th
year of follow-up was 36.7% for workers with animal-
related rhinoconjunctivitis symptoms and 5.2% for those
without allergy symptoms [82]. By contrast, a 24-month
prospective study of apprentice bakers showed that OR
could be diagnosed at an earlier stage in only 20% of cases
of OA [64].
Investigation and diagnostic approach
The investigation of OR includes both assessing the pres-
ence of rhinitis and demonstrating their work-relatedness.
The use of objective methods to assess nasal patency and
parameters of inflammation in nasal secretions mini-
mizes patient misclassification.
The diagnosis needs to be confirmed by means of objec-
tive methods, as misdiagnosis may have substantial social
and financial consequences. The different steps involved
in the diagnosis of OR are the clinical history, nasal exam-
ination, immunological tests (for allergic OR), and nasal
provocation tests (NPT) [see Figure 2].
In addition, the possibility of lower airways involvement
should be carefully evaluated by means of questionnaire,
spirometry, measurement of non-specific airway respon-
siveness [1,83,84] and evaluation of inflammation by
means of exhaled NO [85].
Clinical and occupational history
Detailed medical and occupational history remains a key
step in investigation and diagnosis of OR. The occupa-
tional history should aim at collecting a thorough descrip-
tion of current worker's job duties, processes in adjacent
work areas, recent changes in work processes or materials,
and workplace hygiene conditions. Safety data sheets of
the compounds to which the subject is directly and indi-
rectly exposed should be gathered.
One purpose of the medical history when evaluating OR
is to establish the timing of nasal symptoms in relation
with occupational exposure, as suggested for OA [75,86].
History taking should address the following features:
duration of employment at current job before onset of
symptoms (latency period); agents, tasks or processes
associated with the onset or aggravation of symptoms;
improvement away from work (weekends or prolonged
holidays).
The clinical history should also gather information on the
nature, severity, and impact of rhinitis symptoms. Nasal
symptoms reported by workers suffering from OR are sim-Page 7 of 20
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population with non-occupational rhinitis (i.e. rhinor-
rhea, sneezing, nasal blockage, and itchy nose). Conjunc-
tival complaints often accompany these symptoms,
especially in allergic IgE-mediated OR. [74] A prospective
study carried out among a large cohort of animal-health
apprentices showed that symptoms such as sneezing, rhi-
norrhea and itchy eyes (typical of an early temporal reac-
tion after exposure to an allergen) tended to develop early
after starting exposure, whereas symptoms such as stuffy
nose appeared later [39].
Although an essential step of the diagnostic approach, the
clinical history is not specific enough to establish a diag-
nosis of allergic OR [22,38-41,52].
Nasal examination
Unlike the lower airways, the nose provides a unique
opportunity to visualize macroscopic appearance of the
nasal mucosa using anterior rhinoscopy and nasal endos-
copy. These techniques, however, do not allow quantita-
tive assessment of nasal changes. Their main value is to
rule out other nasal pathologies that may mimic rhinitis
or contribute to aggravate nasal obstruction (e.g, septal
deviations, nasal polyps) in patients with rhinitis.
Physiological assessment
Nasal patency
Objective methods that can be used for assessing nasal
patency during the investigation of OR include rhinoma-
nometry, acoustic rhinometry and peak nasal inspiratory
Diagnostic algorithmFigure 2
Diagnostic algorithm. The figure illustrates the sequential steps for diagnosing occupational rhinitis.
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mon great inter-individual variability that limits their
applicability in clinical practice. Thus, it is not possible to
rely on comparisons with reported values of healthy sub-
jects to make a diagnosis of rhinitis. Nevertheless, the
above methods have well-defined reproducibility,
whereby their use is justified for evaluating nasal response
to NPTs, during which patients act as their own control.
Anterior rhinomanometry measures separately the airway
resistance of each nostril. The technique requires relatively
little patient instruction and is easy to perform, but meas-
urements are difficult when the nostril becomes occluded.
Posterior rhinomanometry assesses the total resistance of
nasal airways through an oral catheter in the pharynx, but
the technique requires collaboration of the patients [89].
Available studies provide conflicting data regarding the
correlation of rhinomanometry with nasal symptoms.
The measurement of peak nasal inspiratory flow (PNIF)
has been proposed as a simple, inexpensive, and readily
available tool for evaluating nasal airway patency [90]. A
good correlation between PNIF and rhinomanometry has
been shown by some reports [91-93], but PNIF is less sen-
sitive in detecting changes in nasal patency [94]. Serial
self-measurements of peak nasal inspiratory flow can be
performed to assess airflow obstruction at the workplace.
Acoustic rhinometry is a relatively new technique that
assesses nasal patency by determining the cross-sectional
area and volume of nasal cavities using the reflection of
sound waves [89]. This technique is non-invasive, repro-
ducible, and requires little cooperation from the patient
[95]. This technique has been useful for demonstrating
cross-shift changes in nasal patency in different industries
and would be promising for workplace challenges.
Nasal inflammation
Inflammatory cells and mediators can be measured in
nasal secretions [27]. Nasal secretions can be collected
and weighted for quantifying the secretory activity, espe-
cially after allergen challenges [96,97]. The use of nasal
lavage in clinical practice is still limited due to great inter-
individual variability and the lack of a standardized and
validated method. Accordingly, this technique is more
useful in situations where subjects serve as their own con-
trols as it occurs during NPT or exposure at the workplace.
Inflammatory cells can also be assessed using nasal biop-
sies [27], whose applicability is limited by their invasive
character, or using nasal scrapings or brush samples,
which are simple and relatively painless procedures [98].
In subjects with allergic rhinitis, a good correlation has
been found between nasal eosinophils and clinical
parameters, including nasal symptoms and nasal patency
[99]. More recently, measurement of nasal nitric oxide
(NO) has been proposed as a non-invasive marker of
nasal inflammation [85,100]. There are currently no data
pertaining to the usefulness of measuring nasal NO in the
investigation of OR.
Non-specific nasal hyperreactivity
Non-specific nasal hyper-reactivity is an important feature
of allergic and non-allergic rhinitis and can be defined as
an increased nasal response to a normal stimulus resulting
in sneezing, nasal congestion, and/or nasal secretion
[101,102]. By contrast to bronchial hyperreactivity in
asthma, nasal hyperreactivity is not so much documented
in occupational rhinitis. Nasal challenge tests with hista-
mine, methacholine [102-104] and cold dry air [105,106]
have been proposed as a method to quantify non-specific
upper airway hyperreactivity. Histamine and metha-
choline responsiveness represent different forms of upper
airway hyperreactivity [101,102]. Histamine is by far the
most commonly used stimulus and hyperreactivity to his-
tamine has been convincingly demonstrated to occur after
allergen provocation [107,108]. Methacholine hyperreac-
tivity has been reported to increase after allergen provoca-
tion [109] but not all studies reproduced these findings
[110]. Intranasal cold dry air has been shown to be supe-
rior to histamine challenge in measuring nasal hyperreac-
tivity in nonallergic non infectious perennial rhinitis
[105,106].
Immunological tests
The demonstration of IgE-mediated sensitization to occu-
pational agents can be achieved by means of skin prick
test and/or assessment of serum allergen-specific IgE anti-
bodies. However, the sensitivity and specificity of immu-
nological tests have almost never been established in
comparison with NPTs. In recent studies, only 42% of
subjects with work-related rhinitis and positive skin-prick
tests to laboratory animals showed a positive NPT with
relevant allergen extracts [52]. Among 47 bakery appren-
tices who developed work-related rhinitis symptoms over
a 2-year period, NPT was positive in the 36 subjects dem-
onstrating IgE sensitization to flour but also in two sub-
jects with negative immunological tests [64]. Positive
immunological test may occur in a substantial proportion
of exposed asymptomatic individuals [63,111-114], so
that the specificity of immunological tests may be lower
than their sensitivity. On the other hand, a negative test
result makes the diagnosis of OR unlikely, provided that
the appropriate allergens have been tested. The major lim-
itation of immunological tests in the investigation of
occupational allergy results from the lack of commercially
available and standardized extracts for most occupational
agents, especially LMW agents.
Nasal provocation tests
These tests are still considered the gold standard for con-
firming the diagnosis of OR [88,115-118]. The major
rationale for performing NPT is to explore, through aPage 9 of 20
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between exposure to a specific occupational agent and
elicitation of the characteristic features of rhinitis. NPTs
can be performed either in the laboratory under control-
led conditions or at work under natural conditions. The
methods that can be used to deliver occupational agents
and to measure nasal response during NPTs have been
critically reviewed [9,26,27,88,97,115-120] and recom-
mendations have been published by the European Acad-
emy of Allergy and Clinical Immunology [119] and the
Committee on Objective Assessment of the Nasal Airways
of the International Rhinologic Society [88]. The method-
ology of NPTs is described in detail in Appendix 1. The
major limitation of these tests results from the fact that
various criteria have been used for defining a positive
response [115-118,120-123], but there is a lack of vali-
dated comparison between these criteria [96].
Diagnostic algorithm
Exploring the work-relatedness of rhinitis symptoms
remains often difficult, since diagnostic procedures
should be adapted to various agents, occupational set-
tings, and available resources. A consensus diagnostic
algorithm has been elaborated (Figure 2) by taking into
account the following practical constraints: (1) the valid-
ity of the tests used for diagnosing OR remains largely
uncertain and (2) the level of reliability may vary accord-
ing to the purpose of the diagnostic evaluation and its
expected socio-economic impact.
The first step includes a thorough clinical and medical his-
tory, as well as nasal examination. If the suspect of an
occupational origin is raised the work-relatedness of the
rhinitis should be confirmed by objective methods. The
second step includes the evaluation of sensitization to
suspected occupational agents through immunological
tests (skin-prick tests and/or determination of specific IgE
antibodies) for most HMW agents and some LMW agents
(i.e. platinum salts, reactive dyes, and acid anhydrides)
[124]. A suggestive clinical history plus a positive immu-
nological tests for a well-standardized extract could be
considered as probable OR.
The next step involves the objective evaluation of the
causal relationship between rhinitis and the work envi-
ronment through NPTs in the laboratory. If NPT is posi-
tive, a definite diagnosis of OR can be established. If NPT
is negative, in the presence of a highly suggestive clinical
history further evaluations of work-related changes in
nasal symptoms, in nasal patency and in nasal inflamma-
tion at the workplace or after a period at work are recom-
mended. Assessment at the workplace may be first
considered when NPT in the laboratory is not feasible (See
Appendix 1).
Management
The management of OR has a two-sided objective: (1)
minimizing nasal symptoms and their impact on the
patients' well-being and (2) preventing the development
of OA. Therapeutic options include environmental inter-
ventions aimed at avoiding exposure to the causal agent
and pharmacologic treatment [21]. Due to the tight rela-
tionships between OR and OA a closer collaboration
between different specialists, ENT, pneumologists and
physicians with expertise in occupational medicine and in
environmental hygiene may be recommended.
Environmental interventions
Treatment strategies should focus on avoidance of expo-
sure to the agent causing allergic OR. However, complete
avoidance of exposure often implies considerable profes-
sional changes for affected workers and is associated with
substantial socio-economic consequences [125,126].
Reduction of exposure can be achieved through different
ways. Helmet respirators have been shown to be partially
effective in reducing the consequences of exposure in
patients with OR and asthma due to laboratory animals
[127] and to latex [128]. However, the use of these protec-
tive respiratory equipments should be considered only for
protecting from peak exposures.
Removal from exposure
Available data indicate that rhinitis could be an early
marker of OA. However, having few quantitative esti-
mates [62,81,82] of the long-term risk of asthma among
patients with OR makes it difficult to decide whether a
worker suffering from this condition should be immedi-
ately and completely removed from causal exposure.
Therefore, advising a worker with OR to avoid exposure
should take into account the following elements.
1. Additional risk factors for the development of asthma
There have been few attempts to determine which patients
with allergic rhinitis have the highest risk of developing
asthma. A study of patients suffering from allergic rhinitis
found that those with non-specific bronchial hyperre-
sponsiveness have a higher risk of asthma [129]. Popula-
tion studies have confirmed that asymptomatic airway
hyperresponsiveness is associated with a more frequent
onset of asthma [130-132]. It has been also demonstrated
that tboth the severity and duration of allergic and non-
allergic rhinitis were important cofactors in determining
the risk of developing asthma [133].
2. Possibilities for minimizing adverse socio-economic consequences
Complete removal from offending exposure may be
implemented with a lower socio-economic impact when
there are possibilities for relocating the worker to unex-
posed jobs within the same company or when possibili-
ties for job retraining are available [126,134].Page 10 of 20
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In workplaces where the level of exposure can be signifi-
cantly reduced, maintaining workers at their job may be
considered a reasonable alternative [135], provided that
workers with OR are submitted to close medical surveil-
lance.
The outcome of OR after environmental interventions or
removal from exposure has been seldom specifically
investigated. In the few follow-up studies of OA that have
evaluated concomitant OR, it has been found that the
severity of rhinitis improved substantially after reduction
of exposure to platinum salts [136] and latex [135,137].
Nevertheless, there is some suggestion that nasal symp-
toms do not completely resolve even after complete
avoidance [135], although it remains unknown whether
allergic OR can lead to persistent functional sequelae. In
non occupational setting, allergic rhinitis is not associated
with remodelling of the nasal mucosa to the same extent
as what has been described in asthmatic airways
[138,139]
Pharmacotherapy and immunotherapy
No studies have addressed pharmacotherapy in OR, either
allergic or non-allergic. Nevertheless, analogous to non-
occupational allergic rhinitis (AR) it may be suggested
that it should be instituted according to evidence-based
guidelines, such as those proposed by the Allergic Rhinitis
and its Impact on Asthma (ARIA) panel of experts http://
www.whiar.com[1]. The effect of non-sedating antihista-
mines and intranasal corticosteroids medications has
almost never been specifically assessed in alleviating
work-related symptoms of rhinitis. However, in allergic
OR, medications should not be considered a suitable
alternative to elimination or reduction of workplace expo-
sure to the sensitising agent.
Several studies have reported some improvement in respi-
ratory symptoms during immunotherapy with purified
rodent proteins, wheat flour extracts, and natural rubber
latex. However, allergen immunotherapy is currently lim-
ited by the unavailability of standardized extracts for most
occupational allergens and should be used with caution
and close supervision until more data are available [140].
Socio-economic impact
The socio-economic impact of OR has almost never been
specifically evaluated and available data thus relate to
other forms of rhinitis. Direct costs attributed to allergic
rhinitis seem to be rather modest [141-144]. There is,
however, growing evidence that important components of
the economic burden of allergic rhinitis are indirect cost
resulting from the worsening of associated airway diseases
(sinusitis, asthma) [145-147], adverse effects of pharma-
cological treatment [148-152], disease-related loss of
work productivity [151,153,154]. The impact of OR on
work productivity has been evaluated in a retrospective
cohort study of Swedish bakers [155]. Bakers reported
having changed their job because of nasal symptoms
more often than control subjects. In a study of Norwegian
bakeries, the authors mentioned that, during a 2-year fol-
low-up, 5 of 180 workers had to 'leave their jobs due
work-related rhinitis, conjunctivitis and/or skin problems
but none as a result of asthma' [22].
There is little information on the psycho-social impact of
OR, although it has been increasingly recognized that
allergic diseases may impair patients' quality of life
[153,156-158]. The negative impact of OR on daily life
has been investigated in only one study conducted among
greenhouse workers [159].
Prevention
Primary prevention actions focus on environmental and
host risk factors in order to prevent the development of
OR. Secondary prevention aims to detect OR at an early
stage and to take appropriate actions to minimize its dura-
tion and severity. Tertiary prevention is applicable only to
patients with established OR (see section on Manage-
ment). Since OR is acknowledged as a risk factor for the
development of OA, the prevention of work-related rhin-
itis may also provide an excellent opportunity to prevent
OA.
Primary prevention
Epidemiological data indicate that the level of exposure to
sensitizing agents is the most important determinant of
IgE-mediated sensitization and OR and, by implication,
reducing or eliminating workplace exposure to sensitising
agents should be the most effective approach for minimiz-
ing the incidence of the disease.
Controlling exposure at the workplace
Examples of effective prevention resulting from reduction
of exposure have been documented in enzyme detergent
production [160-162], platinum refining workers [163],
laboratory workers [164-166], and health care workers
using latex gloves [167-171]. One study found a low rate
of sensitization to diphenylmethane diisocyanate in a ure-
thane mold plant that had been designed to minimize
MDI exposure [86].
Reducing exposure to safe levels remains, however, quite
difficult in field practice, because the threshold level (or
dose) of a sensitizing agent that can elicit respiratory reac-
tions varies widely among sensitised workers [172,173].
Little is known regarding the risk of sensitization at low
concentrations and the existence of a 'no-effect threshold'
[174]. Available information suggest that IgE-mediated
sensitization is unlikely to occur below concentrations ofPage 11 of 20
(page number not for citation purposes)
Respiratory Research 2009, 10:16 http://respiratory-research.com/content/10/1/160.5 mg/m3 for flour dust [60,112,174], 0.25 ng/m3 for
fungal α-amylase allergens [60], 0.7 μg/m3 for urinary rat
allergens [175], and 0.6 ng/m3 for natural rubber latex
allergens [176]. However, methods for measuring air-
borne levels of biological agents are not fully standardized
and are not yet easily available for evaluating the efficacy
of environmental interventions [177].
Identification of susceptible workers
The positive predictive values of available susceptibility
markers are too low for screening out potentially suscep-
tible individuals [178,179]. This is particularly true in the
case of atopy, which is a highly prevalent trait in the gen-
eral population. Excluding atopic individuals from jobs
entailing exposure to HMW allergens would reduce dra-
matically the number of potential new employees and
would be unduly discriminatory. In addition, there is a
role for better education on the risk of sensitization of
those attending vocational schools [178].
Secondary prevention
The short latency period for the incidence of OR indicates
the need for surveillance of individuals at risk in the very
first years of exposure [180]. Surveillance programs
should be implemented during vocational training, since
sensitization to occupational allergens and work-related
nasal symptoms can develop at that time [39,41,53,
71,181-184].
Medical surveillance programmes should include the fol-
lowing components [178,185,186]: (1) pre-placement
and periodic administration of a questionnaire aimed at
detecting work-related symptoms; (2) detection of sensiti-
zation to occupational agents by means of skin prick tests
or serum specific IgE antibodies when these tests are avail-
able and standardized; (3) early referral of symptomatic
and/or sensitized workers for specialized medical assess-
ment, including NPT in the laboratory and/or at the work-
place [52]; and (4) investigation of possible asthma in all
workers with confirmed OR. Unfortunately, the effective-
ness of secondary prevention has been studied in few set-
tings and it is often difficult to distinguish the beneficial
effects attributable to medical surveillance from those
arising as a result of concurrent interventions [162]. In
addition, the predictive value of immunological tests for
the development of OR and OA may be high for some
agents (e.g. platinum salts or acid anhydrides) [187,188],
but much lower for other occupations [62].
Medico-legal aspects
Assessment of impairment/disability
Considering that persistence of exposure to agent causing
allergic OR, will lead to worsening of the disease and is
associated with a risk of asthma, patients with ascertained
OR should, theoretically, be considered impaired on a
permanent basis for the job that caused the condition as
well as for jobs with similar exposures. Evaluating the
level of functional impairment due to OR is hampered by
the absence of reference values for physiological tests.
Impairment may take into account the fact that OR may
be associated with the development of nasal responsive-
ness to a variety of physical and chemical stimuli
[48,49,101,189] and co-morbid conditions, including
olfactory dysfunction, sinusitis, and sleep disorders [190-
192]. Assessment of disability should be based on the
severity of symptoms and their impact on global health
status and quality of life. Quality of life can be assessed
using validated instruments [156-158,193-196], although
these questionnaires are not currently applicable for use
as a clinical tool in individual patients. A classification of
rhinitis severity into "mild" and "moderate/severe" has
been proposed by the Allergic Rhinitis and its Impact on
Asthma (ARIA) based on the impact of symptoms on
sleep and daily life [1]. Rhinitis should be considered
"moderate/severe" when symptoms are troublesome or
when they are associated with sleep disturbance or
impairment in daily activities, including work, school, lei-
sure and sport. Visual analogue scales (VAS) have also
been recommended by the European Consensus on Rhi-
nosinusitis and Nasal Polyps [197] and the American
Taskforce on Practice Parameters [198] for quantifying
rhinitis and rhinosinusistis symptoms. According to the
latest European Position Paper on Rhinosinusitis and
Nasal Polyps 2007 the severity of rhinitis can be divided
into mild, moderate and severe based on total severity vis-
ual analogue scale (VAS) score (0–10 cm): mild (VAS 0–
3), moderate (VAS >3–7), severe (VAS >7–10) [199]. The
simple ARIA grading system of rhinitis severity have been
shown to correlate with impairment in quality of life,
quality of sleep, and work productivity [192,200], VAS
score [201], and health care utilization [202].
Compensation
Policies governing compensation of OR vary widely from
one country to another (Additional file 1). These differ-
ences are due to a number of factors, including adminis-
trative regulations and different ways of defining OR,
determining causality, and evaluating the level of disabil-
ity. The criteria used for determining eligibility for com-
pensation are not uniform. For instance, compensation
may be restricted to a list of agents recognized as causing
OR. The major issue is that these lists are not updated in a
timely manner according to scientific evidence. Relying
on clinical history or on immunological tests for estab-
lishing causality may lead to over- or under-compensation
of OR. In some countries, such as Finland, the causal rela-
tionship between rhinitis and the workplace should be
objectively documented using NPT [97]. Disability result-
ing from OR is usually rated from 5 to 10% in European
countries (Additional file 1), but it is rated higher in some
countries such as South Africa (up to 20% if there is a need
for medication to control symptoms). Depending onPage 12 of 20
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aspects: physiological impairment, work disability, loss of
income, health care costs, and professional retraining.
Available data for OA indicate that the economic conse-
quences of allergic occupational diseases are determined
mainly by socio-demographic factors, while the severity of
the condition has only a minimal effect [126]. Accord-
ingly, it is not surprising that compensation based on
physiological impairment does not adequately offset the
financial consequences of the disease [126]. There is now
a growing consensus that compensation systems should
be directed at accommodating workers to unexposed jobs
within the same company and to offer structured rehabil-
itation programmes when required [179]. Affected work-
ers should also benefit from adequate wage replacement
during the period of professional retraining.
Unmet needs and research areas
Definition and classification
• Characterization of the clinical features and pathophys-
iological mechanisms of 'non-allergic OR' and 'work-exac-
erbated rhinitis'
Epidemiology
• Quantification of the contribution of OR to the general
burden of rhinitis in the general population
• Development and validation of an international ques-
tionnaire to identify OR in epidemiological surveys and
clinical practice
• Further characterization of the role of atopy and smok-
ing in the development of OR
• Elucidation of the interaction between upper and lower
airway responses to sensitizing and irritant agents in the
workplace
Diagnosis
• Standardization of occupational allergen extracts for
skin prick tests and for assessment of serum specific IgE
• Standardization and validation of techniques used for
measuring non-specific nasal hyperreactivity, nasal air-
flow, and nasal inflammation
• Development and standardization of nasal provocation
tests, including standardization of end points, evaluation
of the role of nasal NO measurement, and identification
of the most useful biological markers of nasal response
Management
• Specific assessment of the impact of OR in terms of QoL
and economic burden in order to evaluate the cost-effec-
tiveness of therapeutic and preventive interventions
• Prospective assessment of the efficacy and safety of
immunotherapy with occupational agents in controlling
rhinitis symptoms and preventing the development of OA
Prevention
• Identification of parameters influencing the prognosis
of OR
• Assessment of the effects of environmental interventions
on the clinical and physiological indices of rhinitis, such
as the level of non-specific nasal hyperresponsiveness,
and nasal inflammation
• Assessment of the impact of environmental interven-
tions on the development of OA in subjects with OR
Compensation
• Definition of consensus criteria for grading impairment/
disability resulting from OR
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Methodology of nasal provocation tests
Precautions
NPT should always be carried out in specially equipped
facilities, by trained personnel, and under close medical
supervision. In most subjects, the tests can be performed
on an outpatient basis, restricting hospitalization to sub-
jects who have severe late reactions [119]. Contra-indica-
tions to NPT include pregnancy, recent infectious rhinitis
or sinonasal surgery, atrophic rhinitis, and severe asthma
[116,117]. Medications known to interfere with nasal
response should be withdrawn according to their duration
of action [116,117]. The best time to perform a NPT is in
the morning in order to limit the effects of daily-life stim-
uli (fumes, cold air, spicy foods, and exercise). Baseline
assessment of symptoms and nasal functions should be
performed after adaptation to room temperature for 30
minutes.
It is essential to ensure that the nasal response is specific
to the tested occupational agent by performing a control
test [97]. These control or sham tests make it possible to
detect irritant or non specific hyperresponsiveness. The
control substance is selected according to the nature of the
occupational agent suspected of causing OR, for instance,
diluent for NPTs with aqueous allergen solutions, lactose
powder for NPTs with agent in powder form (flour, drugs,
persulphates, etc.), pine dust for NPTs with wood dusts.
New causal agents have to be tested in control subjects in
order to ascertain the specificity of the nasal response.
Methods of exposure to occupational agents
Exposure in the laboratory
Exposure may take place differently according to the
nature of the agents;
a) Water soluble HMW agents can be administered as
aqueous solutions of allergens. Purified and standardized
allergenic extracts should be used for NPTs when such rea-
gents are available. Alternatively, extracts may be freshly
prepared into saline (phenolated) solutions [97,203]. In
these settings, the level of skin reactivity to the extract can
be used as a guide for determining the initial concentra-
tion that will be delivered to the patient, which will be 10
times more diluted than the concentration eliciting a skin
reaction. In case of negative skin test, the initial dose of
allergen should be in the range of 1:10.000 to 1:5000 wt/
vol or 50 to 100 PNU [116,117,119]. Aqueous solutions
can be delivered using metered dose devices (sprays) as
recently reviewed [118] or by means of nebulizers gener-
ating aerosols according to dosimeter or tidal breathing
protocols. Challenges may regard only one or both nos-
trils. The latter could avoid the influence of the nasal cycle
when monitoring nasal patency [88]. Using allergen solu-
tions offers the advantage of delivering quantified doses
and being a reproducible technique. The limitation of this
method is that the delivered extract may not represent the
native allergens due to purification and extraction proce-
dures, which may potentially lead to falsely negative test.
Other methods of exposure such as syringes, pipettes,
paper discs, and cotton pads [117] should be discouraged
because they do not reproduce natural exposure [118].
b) For all other agents, exposure can be produced in vari-
ous ways, depending on the chemical properties and the
physical state of the agent suspected of causing OR. The
agent may be delivered as an aerosol, vapour, gas or dry
particles by reproducing as much as possible the condi-
tions of exposure occurring at the workplace. In some
cases exposure may be obtained by asking subjects to
reproduce their usual work under close supervision [204].
All these tests should be performed in specifically dedi-
cated challenge rooms. Ideally, the concentration of the
agent should be controlled and maintained below permis-
sible threshold levels. The level of total and respirable
dust and, in some cases (e.g. isocyanates), the concentra-
tion of chemicals can be continuously monitored and
modified during NPTs. The duration of challenge expo-
sure should be gradually increased under close monitor-
ing of nasal response. Subjects should be exposed for up
to 2 hours before the test can be considered negative
[204,205].
Workplace exposure
Workplace challenges may be considered when exposure
to specific suspected agents is not possible, which may
occur in the following settings: (1) no sensitizing agent
has been firmly identified at work, (2) multiple poten-
tially sensitizing agents are present at the workplace, or
(3) the conditions of exposure at work cannot be repro-
duced in the laboratory (e.g. complex industrial proc-
esses) [206] 4) NPTs in the lab are not feasible for
unavailability of equipped facilities. During these tests,
the worker performs his or her usual tasks, and indices of
nasal response are recorded before, during and after one
(or several) work shift(s) with a time-schedule similar to
that used during laboratory NPTs. Each patient should be
compared to itself during a control day in order to ascer-
tain sufficient reproducibility of outcome parameters.
NPT at the workplace can also be a useful tool to investi-
gate irritant-induced OR and work-exacerbated rhinitis
[207,208].
Assessment of nasal response
NPTs may induce immediate and/or late response. The
European Academy of Allergy and Clinical Immunology's
recommendation for monitoring of nasal response entails
assessment at 5, 10, 20, 30, 45, 60 minutes post-exposure,
and then every hour for 10 hours after the end of the chal-
lenge exposure [119]. Several parameters (see clinical
assessment) can be used for assessing nasal responses dur-
ing NPT, including [9,26,27,88,115-122,209] symptomsPage 14 of 20
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logue scales (VAS)] [199] nasal patency (i.e., using rhi-
nomanometry, acoustic rhinometry and/or peak nasal
inspiratory flow), and nasal inflammatory response (i.e.,
volume of nasal secretions, eosinophil counts and con-
centrations of mediators in nasal secretions). Each of
these methods has its own advantages and limitations,
and their reproducibility has not been studied in large
scale studies. There is general agreement that both subjec-
tive and objective indices must be considered, but unlike
bronchial provocation tests, end-points for NPT are not
standardized nor validated. Most frequently, the assess-
ment of the response is made by measuring symptom
score and changes in nasal patency [115,120]. There is,
however, accumulating evidence that assessment of
inflammatory cells (especially, eosinophils) and media-
tors of inflammation (e.g. eosinophil cationic protein,
tryptase) in nasal secretions could increase the specificity
of NPTs with HMW [123,210-212] and LMW [213,214]
agents and could be helpful for minimizing patient mis-
classification. A recent study found that NPT with com-
mon allergens induced a decrease in the level of nasal NO,
which was followed by an increase at 7 and 24 hours post-
challenge [215]. The role of nasal NO as a biomarker of
airway inflammation during NPTs with occupational
agents requires further investigation.
Pitfalls
A false-negative response on NPTs may occur if the wrong
agent has been used, if the exposure conditions are not
comparable with those encountered at the workplace, if
the patient has been away from work for a long time [216]
or if the patient is under nasal steroid treatment.
The most frequent reason for false-positive results in the
measurements of nasal patency during NPTs is the effects
of the nasal cycle. Other potential causes of false-positive
results include a general hyperreactivity of nasal mucosa
resulting from preceding exposure to allergens or irritants
and episodes of rhinosinusitis ('nasal priming') [118,217-
219].
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